Eye injection shows promise for diabetic retinopathy
NCT ID NCT03006081
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether aflibercept injections into the eye can improve areas of poor blood flow in the retina of people with diabetic retinopathy. 38 adults with nonproliferative diabetic retinopathy received the treatment. The goal was to see if the drug could reduce the risk of vision-threatening complications like bleeding or swelling.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan medical center
Seoul, Seoul, 05505, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI eye doctor: could software catch diabetic blindness sooner?
- Can eye scans reveal hidden clues about diabetes damage?
- AI could predict which eye treatments work best for Diabetes-Related vision loss
- New eye drug aims to restore vision in Diabetes-Related swelling
- New eye drug aims to restore vision in Diabetes-Related swelling
- Eye scans could spot Diabetes-Related vision damage years early